Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/24251
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18074/20272 (89%)
Visitors : 4088336      Online Users : 3254
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/24251


    Title: Synthesis of Designed Dextromethorphan Derivatives as Potential Neuroprotective Agents
    Authors: Huey-Chwen Juang (莊惠淳)
    Wen-Hsin Huang (黃文鑫)
    Ann-Ron Lee (李安榮)
    Date: 2011
    Issue Date: 2011-06-23 14:57:36 (UTC+8)
    Abstract: Research in neuroprotection is essential and eager for the development of therapies for neurodegenerative diseases such Alzheimer's disease and Parkinson's disease (PD) important on age-related diseases. Since the primary machinery for the production of neurotoxic factor and pro-inflammatory such as ROS, which cause dopamine (DA) neuron damage in microglia is NADPH oxidase (also called phagocyte oxidase, or PHOX), researches indicated that vital to the neuroprotective effect of DM acts on the NADPH oxidase activity. Dextromethorphan (DM) is originally a dextrorotary morphinan antitussive drug, which has been proven as a potential neuroprotective drug. 3-Hydroxymorphinan (3-HM) has shown the most potency for protect DA neurons among DM and DM's metabolite family, dextrophan (DX), 3-methoxymorphinan (3-MM), and 3-hydroxymorphinan (3-HM). Not only does 3-HM effectively inhibit microglia to reduce neurotoxicity, but also it stimulates astrocyte secretion neurotrophic factors to protect DA neurons. This newly discovered capacity to reduce microglial activation may pave a new path for potential use of DM-related compounds in treating neurodegenerative diseases. In search of neuroprotective agents the structural modification of DM was substantially conducted in our laboratories. Those target compounds are under pharmacological evaluations by in vitro suppressing the production of nitric oxide (NO) and reactive oxygen species (ROS) in LPS-elicited microglia cells and for further a SAR study.
    Relation: 2011年台俄有機、藥物與生物化學交流暨藥物化學研討會,起迄日:2011/04/06~2011/04/05,地點:溪頭台大實驗林
    Appears in Collections:[Pharmacy and Science] 2011 Taiwanese-Russian Organic, Medicinal and Bio Chemistry Interactions & PST Medicinal Chemistry Symposium

    Files in This Item:

    File Description SizeFormat
    pp-35.pdf81KbAdobe PDF634View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback